In this episode, Natalie S. Callander, MD, and Shaji Kumar, MD, answer audience questions from a live CCO Webinar on relapsed/refractory myeloma regarding challenges in treating patients in this setting, including optimizing treatment choices and sequencing of treatments, MRD testing in myeloma, promising BCMA-targeted agents, the promise and value of CAR T-cell therapy in myeloma, and more.Presenters:Natalie S. Callander, MDProfessor of Medicine Director, Myeloma Clinical Program University of Wisconsin Carbone Cancer CenterMadison, WisconsinShaji Kumar, MDDepartment of HematologyMayo ClinicRochester, MinnesotaContent based on an online CME program supported by educational grants from GlaxoSmithKline LLC and Sanofi Genzyme.Link to full program, including associated downloadable slidesets: https://bit.ly/3gT324y

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related